Good work CMA!

I see that Advanz claimed: But a spokesman for Advanz said: "We utterly disagree with the CMA's decision on the pricing of liothyronine tablets and will be appealing. "At all times, Advanz Pharma acted in the interest of patients, investing significantly to keep this medicine on the market to the specifications required by the Medicines and Healthcare products Regulatory Agency (MHRA)." (From BBC News site) They would likely have helped patients by withdrawing from the market and ensuring the NHS bought liothyronine from Germany (£31 for 100 tablets rather than £249 for 28 in the UK) - or other possible suppliers in Netherlands, France, Greece, etc. How can a company claim to be charging this much simply in order to manufacture a medicine than has been available for fifty years? That is actually not even manufactured by Advanz (they get it produced on contract). They have put it about that they were investing in the factory facilities yet they don't own the factory. Anyway, isn't much of business based on investing in something then making it back afterwards - not charging in advance. I also notice that Advanz have said they will appeal. I sincerely hope that an unjustified appeal can increase jeopardy - for example, by increasing fines or wasting the time of those who have to hear the appeal. If this is showing concern for patients' interests, let us be thankful that there has at last been sort sort of reckoning.